Chiron Off The Hook For Securities Violations
In October 2004, the SEC began informally investigating Chiron in connection with the unexpected suspension of Chiron's license to manufacture an influenza virus vaccine, Fluviron, by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency. The suspension was due to concerns of contamination.
U.S. securities regulators wanted to know what the company could and should have told investors about its vaccine manufacturing...
To view the full article, register now.